Correction
Correction to: Duration of Dual Antiplatelet Therapy: A Systematic Review
for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual
Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of
the American College of Cardiology/American Heart Association Task Force
on Clinical Practice Guidelines
Downloaded from http://circ.ahajournals.org/ by guest on June 15, 2017
In the article by Bittl et al, “Duration of Dual Antiplatelet Therapy: A Systematic Review for
the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy
in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines,” which
published online March 29, 2016, and appeared in the September 6, 2016, issue of the
journal (Circulation. 2016;134:e156–e178. DOI: 10.1161/CIR.0000000000000405.),
several corrections were needed.
1. On page e156, in the Abstract, several corrections have been made:
• In the fourth paragraph, the second sentence read, “Bayesian models
confirmed the primary analysis. A2) Use of DAPT for 18 to 48 months,
compared with use for 6 to 12 months, was associated with no difference in incidence of all-cause death...(OR: 0.42; 95% CI: 0.24 to 0.74).”
It has been updated to read, “Bayesian models confirmed the primary
analysis. A2) Use of DAPT for 18 to 48 months, compared with use for 6
to 12 months, was associated with no difference in incidence of all-cause
death...(OR: 0.45; 95% CI: 0.24 to 0.74).”
• In the last paragraph, the last sentence read, “In patients whose coronary
thrombotic risk was defined by a prior MI rather than by DES implantation,
the primary analysis provided moderately strong evidence ....” It has been
updated to read, “In patients whose coronary thrombotic risk was defined
by a prior MI rather than by DES implantation, the primary analysis provides moderately strong evidence ....”
2. On page e159, right-hand column, first paragraph, the first sentence read,
“ARCTIC INTERRUPTION (Dual-Antiplatelet Treatment Beyond 1 Year After
Drug-Eluting Stent Implantation) trial,19 which was….” It has been updated to
read, “ARCTIC Interruption (Assessment by a Double Randomisation of a Conventional Antiplatelet Strategy Versus a Monitoring-Guided Strategy for Drug
Eluting Stent Implantation and of Treatment Interruption Versus Continuation 1
Year After Stenting) trial,19 which was….”
3. On page e159, right-hand column, in the second paragraph, several corrections have been made:
• The second sentence read, “In the OPTIMIZE (Three Versus 12 Months
of Dual Antiplatelet Therapy After Zotarolimus-Eluting Stents) trial,18 investigators observed….” It has been updated to read, “In the OPTIMIZE
(Optimized Duration of Clopidogrel Therapy Following Treatment With the
Zotarolimus-Eluting Stent in Real-World Clinical Practice) trial,18 investigators observed….”
• The fourth sentence read, “With rates of the primary endpoint...(risk difference: 0.8%; 95% CI: 2.4% to 1.7%)....” It has been updated to read, “With
rates of the primary endpoint...(risk difference: 0.8%; 95% CI: -2.4% to
1.7%)....”
Circulation. 2016;134:e195–e197. DOI: 10.1161/CIR.0000000000000453
Circulation is available at
http://circ.ahajournals.org.
© 2016 American Heart
Association, Inc.
September 6, 2016
e195
Correction to: Duration of DAPT ERC Systematic Review Report
Downloaded from http://circ.ahajournals.org/ by guest on June 15, 2017
• The fifth sentence read, “The ITALIC (6-Versus
24-Month Dual Antiplatelet Therapy After
Implantation of Drug-Eluting Stent in Patients
Nonresistant to Aspirin) study21 compared….”
It has been updated to read, “The ITALIC (Is
There A Life for DES After Discontinuation of
Clopidogrel) study21 compared….”
• The sixth sentence read, “With small differences in the primary endpoint between the 2
groups (risk difference: 0.11%; 95% CI: 1.04%
to 1.26%)....” It has been updated to read,
“With small differences in the primary endpoint
between the 2 groups (risk difference: 0.11%;
95% CI: -1.04% to 1.26%)....”
4. On page e160, right-hand column, in the second
paragraph, the first sentence read, “Similar results
were obtained with Bayesian hierarchical metaanalyses...stent thrombosis (OR: 0.42; 95% BCI:
0.19 to 0.87), and the primary study endpoints
(OR: 0.86; 95% BCI: 0.70 to 1.07).” It has been
updated to read, “Similar results were obtained
with Bayesian hierarchical meta-analyses...stent
thrombosis (OR: 0.45; 95% BCI: 0.19 to 0.87)....”
5.On page e160, right-hand column, third paragraph, the last sentence read, “This corresponded
to a nonsignificant number needed to treat to number needed to harm of 512, with wide confidence
intervals extending from -172 to 892.” It has been
updated to read, “This corresponded to a nonsignificant number needed to harm of 512, with wide
confidence intervals extending from -172 to 892.”
6. On page e162, left-hand column, in the third paragraph, the second sentence read, “Among trials of
DAPT prolongation in the setting of PCI, the DAPT
trial23 alone evaluated ....” It has been updated to
read, “Among trials of DAPT prolongation in the
setting of PCI, the DAPT trial23 evaluated ....”
7. On page e162, right-hand column, first paragraph,
the last sentence read, “The magnitude of effort
required to obtain such outcomes can be illustrated in a population plot (Figure 8), which also
shows that ischemic events were seldom observed
in the overall population and only partly prevented
by active treatment.” It has been updated to read,
“The magnitude of effort required to obtain such
outcomes can be illustrated in a population plot
(Figure 8), which also shows that for every 1000
patients treated per year, 996 experienced no benefit (970 without an ischemic event plus 26 who
had an ischemic event despite prolonged DAPT).”
8. On page e164, left-hand column, second paragraph, the second sentence read, “An investigation using a plausible worst-case sensitivity
analysis found a significant 19% increase in mortality rate with prolonged DAPT62; a systemic
review using a pairwise meta-analysis….” It has
e196
September 6, 2016
been updated to read, “An investigation using a
plausible worst-case sensitivity analysis found a
significant 19% increase in mortality rate with
prolonged DAPT62; a systematic review using a
pairwise meta-analysis….”
9. On pages e167 and e168, in the References section, several updates have been made:
• Reference 30 read, “He Y, Bittl JA, Wouhib
A, et al. Case study in cardiovascular medicine: unprotected left main coronary artery
disease. In: Biondi-Zoccai G, ed. Network
Meta-Analysis: Evidence Synthesis With
Mixed Treatment Comparison. 1st ed.
Hauppauge, NY: Nova Science Publishers,
Inc.; 2014:285–386.” It has been updated to
read, “He Y, Bittl JA, Wouhib A, et al. Case
study in cardiovascular medicine: unprotected left main coronary artery disease. In:
Biondi-Zoccai G, ed. Network Meta-Analysis:
Evidence Synthesis With Mixed Treatment
Comparison. Hauppauge, NY: Nova Science
Publishers, Inc.; 2014:285–386.”
• Reference 61 read, “Morey-Vargas OL,
Zeballos-Palacios OL, Gionfriddo MR, et al.
The hierarchy of evidence. In: Biondi-Zoccai
G, ed. Network Meta-Analysis: Evidence
Synthesis With Mixed Treatment Comparison.
New York, NY: Nova Science Publishers,
Inc.; 2014:3–20.” It has been updated to
read, “Morey-Vargas OL, Zeballos-Palacios
OL, Gionfriddo MR, et al. The hierarchy of
evidence. In: Biondi-Zoccai G, ed. Network
Meta-Analysis: Evidence Synthesis With
Mixed Treatment Comparison. Hauppauge,
NY: Nova Science Publishers, Inc.;
2014:3–20.”
• Reference 62 read, “Spencer FA, Prasad M,
Vandvik PO, et al. Longer-versus shorter-duration dual-antiplatelet therapy after drug-eluting
stent placement: a systematic review and amteanalysis. Ann Intern Med. 2015;163:118–26.”
It has been updated to read, “Spencer FA,
Prasad M, Vandvik PO, et al. Longer-versus
shorter-duration dual-antiplatelet therapy after
drug-eluting stent placement: a systematic
review and meta-analysis. Ann Intern Med.
2015;163:118–26.”
10. On page e169, Table 1, sixth row, in the first column, the cell read, “ARTIC (12 vs. 18 mo).19” It has
been updated to read, “ARTIC Interruption (12 vs.
18 mo).19”
11. On page e170, Table 2, several corrections have
been made:
• In the first row, in the first column, the cell
read, “DES LATE.14” It has been updated to
read, “DES LATE.13”
Circulation. 2016;134:e195–e197. DOI: 10.1161/CIR.0000000000000453
Correction to: Duration of DAPT ERC Systematic Review Report
• In the second row, in the first column, the cell
read, “PRODIGY.15” It has been updated to
read, “PRODIGY.14,15”
• In the sixth row, in the first column, the cell
read, “ARTIC (12 vs. 18 mo).19)” It has been
updated to read, “ARTIC Interruption (12 vs.
18 mo).19”
• In the 12th row, in the first column, the cell
read, “CHARISMA.34,43” It has been updated to
read, “CHARISMA.33,42”
12. On page e173, Figure 4, in the legend, the third
sentence read, “The prior distribution is consistent with the likelihood (red), which….” It has
been updated to read, “The prior distribution is
consistent and overlaps with the likelihood (red),
which….”
These corrections have been made to the print version
and to the current online version of the article, which is
available at http://circ.ahajournals.org/content/134/10/
e156.full.
Downloaded from http://circ.ahajournals.org/ by guest on June 15, 2017
Circulation. 2016;134:e195–e197. DOI: 10.1161/CIR.0000000000000453
September 6, 2016
e197
Correction to: Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016
ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in
Patients With Coronary Artery Disease: A Report of the American College of
Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Downloaded from http://circ.ahajournals.org/ by guest on June 15, 2017
Circulation. 2016;134:e195-e197
doi: 10.1161/CIR.0000000000000453
Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2016 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539
The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://circ.ahajournals.org/content/134/10/e195
Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published
in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial
Office. Once the online version of the published article for which permission is being requested is located,
click Request Permissions in the middle column of the Web page under Services. Further information about
this process is available in the Permissions and Rights Question and Answer document.
Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints
Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org//subscriptions/